The description of the peer review is off target. This is what all reputable biotech, pharmaceutical or any high level profession does. It it isn’t slowing anything. It can accelerate partnership, approvals after Phase 3, and is a necessary and vital part of NGIOs research and development for them to be taken seriously.

Worrying about revenues from sales for a developmental life science or biotech as a way to place a valuation on them is misplaced worries. The overwhelming majority of similar companies that are valued in the billions have no revenue.

Putting zero on that as some type of false marker makes no sense. And I’m pretty certain no one wants that NGIO listing on Nasdaq more than Joe and his team. If it was easy as a message board post saying “do it now” it would be listed and they can raise significant capital to actually pay themselves.